Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E. Nybakken, Keith Pratz, Judith Karp, B. Douglas Smith, Mark Levis

Blood (2012) 120 (20): 4205–4214.

https://doi.org/10.1182/blood-2012-01-402545

Published: 2012

Includes: Supplemental data

Journal Articles

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia

Brian Parkin, Harry Erba, Peter Ouillette, Diane Roulston, Anjali Purkayastha, Judith Karp, Moshe Talpaz, Lisa Kujawski, Sajid Shakhan, Cheng Li, Kerby Shedden, Sami N. Malek

Blood (2010) 116 (23): 4958–4967.

https://doi.org/10.1182/blood-2010-01-266999

Published: 2010

Includes: Supplemental data

Journal Articles

Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients.

Jeffrey E Lancet, MD, Gail J. Roboz, MD, Larry D. Cripe, Michael Maris, MD, Alan F List, MD, Judith Fox, Glenn C Michelson, MD, Judith Karp

Blood (2009) 114 (22): 635.

https://doi.org/10.1182/blood.V114.22.635.635

Published: 2009

Journal Articles

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Michael W Evans, MD, MPH, Anthony Sung, MD, Ivana Gojo, MD, Michael L Tidwell, RN, CRNP, Jacqueline Greer, RN, BSN, Mark Levis, Judith Karp, Maria R Baer, MD

Blood (2009) 114 (22): 4126.

https://doi.org/10.1182/blood.V114.22.4126.4126

Published: 2009

Journal Articles

Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210- BCR/ABL Expressing Cell Lines.

Rachel E. Rau, MD, Emily McIntyre, Scott H. Kaufmann, MD, PhD, Igor Espinoza-Delgado, MD, Judith Karp, Patrick Brown, MD

Blood (2009) 114 (22): 2742.

https://doi.org/10.1182/blood.V114.22.2742.2742

Published: 2009

Journal Articles

Immune Recovery after Timed Sequential Therapy in Acute Myelogenous Leukemia: Discordant Recovery of Naïve T Lymphocytes and Antigen Driven Regulatory T Cells.

Allan D. Hess, PhD, Christian Meyer, Christopher Thoburn, Ferdynand Kos, Christopher Gocke, Hyam Levitsky, Judith Karp

Blood (2008) 112 (11): 947.

https://doi.org/10.1182/blood.V112.11.947.947

Published: 2008

Journal Articles

Flavopiridol Down-Regulates Genes Involved in Cell Cycle Regulation and Tumor Progression in Adults with Refractory or Poor-Risk Acute Leukemia.

Linda Resar, M.D., Joelle Hillion, Ph.D., Katrina Alino, R.N., B.S.N., Michelle Rudek, Pharm.D., Ph.D., Judith Karp, M.D.

Blood (2008) 112 (11): 953.

https://doi.org/10.1182/blood.V112.11.953.953

Published: 2008

Journal Articles

Can Genomic Copy Number Variants Be a Part of Complex Genetic Traits Predisposing to Marrow Failure?.

Christine O’Keefe, PhD, Lukasz Gondek, MD, Marcin Wlodarski, MD, Judith Karp, MD, Michael McDevitt, MD, Jaroslaw P. Maciejewski, MD/PhD

Blood (2007) 110 (11): 106.

https://doi.org/10.1182/blood.V110.11.106.106

Published: 2007

Journal Articles

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Jeffrey Lancet, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Sem Bastien, R.N., Katrina Alino, R.N., Glenn Michelson, M.D., Judith Karp, M.D.

Blood (2007) 110 (11): 442.

https://doi.org/10.1182/blood.V110.11.442.442

Published: 2007

Journal Articles

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

Joya Chandra, Jeannette Tracy, David Loegering, Karen Flatten, Srdan Verstovsek, Miloslav Beran, Mercedes Gorre, Zeev Estrov, Nicholas Donato, Moshe Talpaz, Charles Sawyers, Kapil Bhalla, Judith Karp, Edward Sausville, Scott H. Kaufmann

Blood (2006) 107 (6): 2501–2506.

https://doi.org/10.1182/blood-2005-07-2966

Published: 2006

Journal Articles

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Francis Giles, MD, Susan O’Brien, MD, David Rizzieri, MD, Judith Karp, MD, Maureen Cooper, MD, Ghulam Mufti, MD, Bonny Johnson, MSN, Verena Karsten, PhD, Norbert Vey, MD

Blood (2005) 106 (11): 2786.

https://doi.org/10.1182/blood.V106.11.2786.2786

Published: 2005

Journal Articles

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Francis Giles, MD, David Rizzieri, MD, Judith Karp, MD, Norbert Vey, MD, Khuda Khan, MD, Ghulam Mufti, MD, Diana Hudak, Verena Karsten, PhD, Susan O’Brien, MD

Blood (2005) 106 (11): 2787.

https://doi.org/10.1182/blood.V106.11.2787.2787

Published: 2005

Journal Articles

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Mark Levis, MD, PhD, Adam Stine, BS, Rosalyn, Pham BS, B. Douglas Smith, MD, Judith Karp, MD, Richard Stone, MD, Elihu Estey, MD, Frank Giles, MD, Hagop Kantarjian, MD, Pamela Cohen, MD, Yanfeng Wang, PhD, Donald Small, MD, PhD

Blood (2005) 106 (11): 2463.

https://doi.org/10.1182/blood.V106.11.2463.2463

Published: 2005

Journal Articles

Phase II Study of Timed Sequential Therapy (TST) with Topotecan, Cytosine Arabinoside (ARA-C), and Mitoxantrone (TAM) Induction Therapy Followed by Non-Cross-Resistant Consolidation Chemotherapy for Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Ivana Gojo, MD, Lawrence Morris, MD, Chuanfa Guo, PhD, Meyer Heyman, MD, Michael Tidwell, NP, Jackie Greer, RN, Maureen Klein, RN, Marianne Irani, PharmD, Judith Karp, MD

Blood (2004) 104 (11): 876.

https://doi.org/10.1182/blood.V104.11.876.876

Published: 2004

NARROW

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia

Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia.

Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients.

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210- BCR/ABL Expressing Cell Lines.

Immune Recovery after Timed Sequential Therapy in Acute Myelogenous Leukemia: Discordant Recovery of Naïve T Lymphocytes and Antigen Driven Regulatory T Cells.

Flavopiridol Down-Regulates Genes Involved in Cell Cycle Regulation and Tumor Progression in Adults with Refractory or Poor-Risk Acute Leukemia.

Can Genomic Copy Number Variants Be a Part of Complex Genetic Traits Predisposing to Marrow Failure?.

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Phase II Study of Timed Sequential Therapy (TST) with Topotecan, Cytosine Arabinoside (ARA-C), and Mitoxantrone (TAM) Induction Therapy Followed by Non-Cross-Resistant Consolidation Chemotherapy for Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only